OCULAR THERAPEUTIX INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
OCUL$6.61-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
(In thousands, except share data)
| | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | |
| · · · · · · · · · · · · · · Total | |||||||||||||||
| · · · · · · · · Additional · · · · · Stockholders’ | |||||||||||||||
| · · · Common Stock · · Paid-in · · Accumulated · · Equity | |||||||||||||||
| · Shares · Par Value · Capital · Deficit · (Deficit) | |||||||||||||||
| Balances at December 31, 2020 | 75,996,732 | | | 8 | | | 615,338 | | | (539,251) | | | 76,095 | ||
| Issuance of common stock upon exercise of stock options | 598,923 | | — | | | 2,586 | | — | | 2,586 | |||||
| Issuance of common stock in connection with employee stock purchase plan | 124,548 | | — | | | 985 | | — | | 985 | |||||
| Issuance of common stock upon cashless exercise of warrant | 11,737 | | — | | | — | | — | | — | |||||
| Common stock issuance costs | — | | | — | | | (91) | | | — | | | (91) | ||
| Stock-based compensation expense | — | | — | | 14,977 | | — | | 14,977 | ||||||
| Net loss | — | | — | | — | | (6,553) | | (6,553) | ||||||
| Balances at December 31, 2021 | 76,731,940 | | | 8 | | | 633,795 | | | (545,804) | | | 87,999 | ||
| Issuance of common stock upon exercise of stock options | 137,502 | | | — | | | 514 | | | — | | | 514 | ||
| Issuance of common stock in connection with employee stock purchase plan | 332,377 | | | — | | | 940 | | | — | | | 940 | ||
| Stock-based compensation expense | — | | | — | | | 16,964 | | | — | | | 16,964 | ||
| Net loss | — | | | — | | | — | | | (71,038) | | | (71,038) | ||
| Balances at December 31, 2022 | 77,201,819 | | | 8 | | | 652,213 | | | (616,842) | | | 35,379 | ||
| Issuance of common stock upon exercise of stock options | | 141,952 | | | — | | | 551 | | | — | | | 551 | |
| Issuance of common stock in connection with employee stock purchase plan | | 290,691 | | | — | | | 851 | | | — | | | 851 | |
| Issuance of common stock upon public offering, net of issuance costs | | | 36,934,926 | | | 4 | | | 117,257 | | | — | | | 117,261 |
| Issuance of common stock upon vesting of restricted stock units | | | 393,805 | | | — | | | — | | | — | | | — |
| Stock-based compensation expense | | — | | | — | | | 17,825 | | | — | | | 17,825 | |
| Net Loss | | — | | | — | | | — | | | (80,736) | | | (80,736) | |
| Balances at December 31, 2023 | 114,963,193 | | $12 | | $788,697 | | $(697,578) | | $91,131 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.